Cerner Enviza, Paris, France
Xavier Guillaume , Dahbia Horchi , Jorge Gomez , Patrick Hlavacek , Jinma Ren , Alex Schepart , Didem Aydin , Marco DiBonaventura
Background: Many patients with MM relapse or become refractory to various therapeutic approaches and typically cycle through many lines of treatment. The present study sought to understand how patients with TCR MM (ie, refractory to ≥1 PI, ≥1 IMiD, and ≥1 anti-CD38 therapy) are managed across various countries. Methods: A non-interventional, retrospective chart review study was conducted across the US, Canada (CA), the UK, France (FR), Germany (DE), Italy (IT), and Spain (ES). Oncologists/hematologists were recruited to abstract medical chart information into an electronic case report form from eligible MM patients (eg, refractory to ≥1 IMiD, ≥1 PI, and ≥1 anti-CD38 antibody treatment, ECOG≤2, and initiated their first therapy after their TCR status [ie, their index therapy] between 1/1/2018 and 12/31/2020 to ensure at least 1 year of follow-up). Abstractions were performed from January through April 2022. Demographics, clinical characteristics, and treatment patterns were descriptively analyzed and reported here. Results: N = 314 patients with TCR MM were included (56.7% male; median age = 70). Clinical characteristics were similar to other TCR MM studies (eg, 26.1% had an ECOG score of 2, 25.8% had high cytogenetic risk (ie, t(4:14), t(14:16), and/or del(17p), and 10.2% had extramedullary disease). Patients received a median of 3 treatment lines prior to their index therapy, with 70 unique treatment regimens reported as part of their index therapy line (Table 1). The most common regimens (> 10%) were Pd and Kd. Conclusions: This global chart review across the US, Canada, and Western Europe highlights the consistent lack of a standard of care for the management of MM among patients who are refractory to the three main classes of therapies.
Overall N = 314 | CA N = 21 | FR N = 67 | DE N = 27 | IT N = 55 | ES N = 46 | UK N = 65 | US N = 33 | |
---|---|---|---|---|---|---|---|---|
Pd | 60 (19.1%) | 5 (23.8%) | 8 (11.9%) | 11 (40.7%) | 10 (18.2%) | 7 (15.2%) | 17 (26.2%) | 2 (6.06%) |
Kd | 37 (11.8%) | 1 (4.76%) | 14 (20.9%) | 4 (14.8%) | 4 (7.27%) | 12 (26.1%) | - | 2 (6.06%) |
Pd+Cy | 29 (9.24%) | 1 (4.76%) | 4 (5.97%) | - | 4 (7.27%) | 15 (32.6%) | 5 (7.69%) | - |
RNd | 16 (5.10%) | 3 (14.3%) | 1 (1.49%) | - | - | - | 12 (18.5%) | - |
EPd | 13 (4.14%) | - | - | 1 (3.70%) | 3 (5.45%) | - | - | 9 (27.3%) |
Belantamab | 11 (3.50%) | 1 (4.76%) | 1 (1.49%) | 2 (7.41%) | 3 (5.45%) | 4 (8.70%) | - | - |
Nd | 10 (3.18%) | - | - | - | - | - | 8 (12.3%) | 2 (6.06%) |
CAR-T | 9 (2.87%) | - | 4 (5.97%) | - | - | 1 (2.17%) | - | 4 (12.1%) |
KPd | 8 (2.55%) | - | 4 (5.97%) | - | - | - | - | 4 (12.1%) |
P, pomalidomide; d, dexamethasone; K, carfilzomib; Cy, cyclophosphamide; R, lenalidomide; N, ixazomib; E, elotuzumab.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Andrew J Yee
2023 ASCO Annual Meeting
First Author: Noa Biran
2021 ASCO Annual Meeting
First Author: Cristina Gasparetto
2023 ASCO Annual Meeting
First Author: Ravi K. Goyal